Acurx Pharmaceuticals Announces Intent For Further Discussion With FDA Regarding Ibezapolstat's Phase 3 Clinical Program, Scope Of Its Planned NDA

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release, Q2 earnings

Acurx Pharmaceuticals shares are trading higher after the company announced that the FDA has conditionally accepted the proposed proprietary, or brand name, CIFBEZY for ibezapolstat.

U.S. Patent And Trademark Office Allows Trademark Application For CIFBEZY.

FDA Conditionally Accepts Acurx Pharmaceuticals' Brand Name CIFBEZY for Ibezapolstat

The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTOThese initial milestones will form the basis for the commercial